Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2018-04-16

FDA Approved: TAZORAC — Supplemental Application (Almirall, LLC)

View source ↗

Summary

The FDA approved a supplemental application for TAZORAC (tazarotene) from Almirall, updating the product’s labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TAZORAC (Tazarotene)

Snippet

SUPPL AP for TAZORAC (TAZAROTENE)